BIND Therapeutics: Harnessing the Power of Nanoengineering to Fight Cancer

As diseases get smarter, the power of science and technology also continues to advance to keep up with the challenges posted by medicine. Compared to the approach we used before, medical companies have resorted to using nanoengineering to combat diseases in a different level. By deploying nano medicines, pharmaceutical companies are able to ensure the efficacy of their products, while allowing the body to regenerate naturally.

BIND Therapeutics is one of the medical companies that have deployed the use of this nanoengineering to create novelty therapeutics that would change the future of medicine. Through small molecule therapeutics, the body can naturally regenerate because the therapeutics will leave healthy cells and attack the damaged ones. BIND Therapeutics continue to develop and create Accurins that are designed to concentrate at the site of the disease. These therapeutics are programmable and are designed with specific chemical and physical characteristics. The development of these therapeutics allows new medications to combat cancer at three different levels: cellular, molecular and tissue.

The Accurins that are currently being developed by the company are focused on oncology. The business has several therapeutics in the pipeline that are being developed on their own or through collaborative means with other pharmaceutical companies. Their lead product is named the BIND-014 and is intended to target non-small cell lung cancer and metastatic castrate-resistant prostate cancer. Their second product, the BIND-510 is being developed as a prostate-specific membrane antigen. BIND Therapeutics has a partnership with Roche, Merck, Pfizer, Amgen and AstraZeneca.

BIND Therapeutics is headquartered in Cambridge, Massachusetts and continues to publicly trade on the NASDAQ. The common stocks of the business are marketed under the ticker symbol BIND. The company strongly believes that Accurins are the evolved therapy for cancer and other similar diseases. By continuously investing in their research programs, the business is taking the fight against the Big C, a step further.